Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
Go back to Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer| JAZZ PHARMACEUTICAL (NASDAQ: JAZZ) | Delayed: 230.25 +4.33 (1.92%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $225.92 | 52 Week High | $160.00 | |||
| Open | $225.27 | 52 Week Low | $95.80 | |||
| Day High | $230.94 | P/E | 42.80 | |||
| Day Low | $222.93 | EPS | $5.38 | |||
| Volume | 860,935 | |||||
